Bronchial Thermoplasty (BT), delivered by the Alair™ System, is a minimally invasive and safe outpatient procedure for the treatment of severe asthma in adults. BT is the first and only non-drug therapy for patients with severe asthma, with clinically proven benefits out to 5 years. Learn more at BTforAsthma.com »
Identifying BT Candidates
Asthma symptoms can interfere with your patients' daily lives and contributes to missed days at work school and other activities. The Asthma Impact Survey (AIS-6) is a validated survey that measures the impact of asthma on everyday functioning and a predictor for the risk of future exacerbations. Have your patients take the Asthma Impact Survey on BTforAsthma.com to help them assess if severe asthma is impacting their quality of life.
BT has 5 years of effectiveness and safety data
Learn more about the 5 year clinical safety data that demonstrate benefits of BT are maintained long term.
Click on the individual trial name, below, for additional information on each clinical study.
Treatment With BT
Bronchial Thermoplasty reduces the amount of excess smooth-muscle tissue in the airways. After BT, the airways constrict less, breathing is easier, and there is less likelihood of an asthma attack.
BT is delivered by the Alair™ System in 3 short sessions, using a device called the Alair™ Catheter. No incisions or full anesthesia necessary. Sessions are typically scheduled 3 weeks apart. Each session is routinely performed under moderate sedation and typically takes less than an hour to complete.
As with any procedure, there are risks, and individual results may vary. The most common side effect of BT is temporary worsening of respiratory-related symptoms. This side effect typically occurs within a day of the procedure and resolves within 7 days on average with standard care. There is a small (3.4% per procedure) risk of these symptoms requiring hospitalization.
References: 1. Castro M, et al, for the AIR2 Trial Study Group. Am J Respir Crit Care Med. 2010;181:116-124. 2. Wechsler M, et al, for the AIR2 Trial Study Group. J Allergy Clin Immunol. 2013;132:1295-1302.